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Burden of five healthcare associated
infections in Australia
M. J. Lydeamore1,2*, B. G. Mitchell3,4, T. Bucknall5,6, A. C. Cheng2, P. L. Russo7,8† and A. J. Stewardson2†

Abstract
Background: Healthcare associated infections are of significant burden in Australia and globally. Previous estimates
in Australia have relied on single-site studies, or combinations thereof, which have suggested the burden of these
infections is high in Australia. Here, we estimate the burden of five healthcare associated infections (HAIs) in Australian
public hospitals using a standard international framework, and compare these estimates to those observed in Europe.
Methods: We used data from an Australian point prevalence survey to estimate the burden of HAIs amongst adults
in Australian public hospitals using an incidence-based approach, introduced by the ECDC Burden of Communicable
Diseases in Europe.
Results: We estimate that 170,574 HAIs occur in adults admitted to public hospitals in Australia annually, resulting in
7583 deaths. Hospital acquired pneumonia is the most frequent HAI, followed by surgical site infections, and urinary
tract infections. We find that blood stream infections contribute a small percentage of HAIs, but contribute the highest number of deaths (3207), more than twice that of the second largest, while pneumonia has the higher impact on
years lived with disability.
Conclusion: This study is the first time the national burden of HAIs has been estimated for Australia from point
prevalence data collected using validated surveillance definitions. Per-capita, estimates are similar to that observed in
Europe, but with significantly higher occurrences of bloodstream infections and healthcare-associated pneumonia,
primarily amongst women. Overall, the estimated burden is high and highlights the need for continued investment in
HAI prevention.
Keywords: Healthcare associated infections, Infection control, Nosocomial infection, Epidemiology
Introduction
Healthcare associated infections (HAIs) are associated with increased morbidity and mortality, and excess
healthcare costs [1, 2]. An accurate quantification of HAI
burden is required to prioritise and evaluate infection
prevention interventions. The burden of HAIs overseas
is known to be high [3–8], but previous estimates in an
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Australian setting have relied on a range of opportunistic
reports of incidence [9].
The ECDC introduced a methodology to estimate the
total number of HAI cases from a point prevalence survey [4]. Combined with disease outcome trees, the number of disability adjusted life years (DALYs) and deaths
can also be estimated [10].
A point prevalence survey (PPS) of HAIs was previously conducted across 19 public hospitals in Australia
[11]. We used data from this PPS, combined with admitted patient care data from the Australian Institute of
Health and Welfare [12]. The aim was to estimate the
population level burden in Australia of five HAIs: healthcare-associated Clostridioides difficile infection (CDI),
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healthcare-associated bloodstream infection (BSI), urinary tract infection (UTI), healthcare acquired pneumonia (HAP) and surgical site infection (SSI). These
estimates are also compared with previous literaturebased estimates of the burden of HAIs in Australia, and
with similar PPS studies conducted in Europe.

Methods
Study population and study design

The Australian PPS data used in this study was collected
in 2018 in a sample of adult patients in 19 public, large
acute care hospitals. The surveillance methodology was
based on the European Centre for Disease Prevention
and Control (ECDC) PPS protocol [13]. The types of
HAIs that were selected for this study were as described
in Cassini et. al [4]. HAIs were defined as per the ECDC
protocol [13], with data collected by two research assistants, and entered into a secure online web-based survey
tool.
A total of 2767 patients were sampled. Results from
this PPS have previously been reported in detail [11, 14].
The median age of patients was 67 (IQR 49–79, range
18–104). Of these, 52.9% (1465) were male, 46.6% (1289)
female and 0.5% [13] unknown/other. A majority (85.7%)
of patients were from major city hospitals, with the
remaining 14.3% from regional services.
Outcome measures

As well as the number of cases, we estimate deaths and
DALYs for each condition. DALYs are a composite measure of years lived with disability (YLDs) and years life
lost (YLLs), accounting for incidence, severity, and mortality of disease simultaneously. They also provide a way
to compare the impact of disease across conditions, as
opposed to simply ranking by incidence of prevalence.
Estimation methodology

The same approach as used for the estimation of the
burden of HAIs in Germany was applied to this PPS [3],
except for the choices of age strata. As the Australian PPS
was only collected in adults, and involved a smaller sample size, strata were chosen to be 18–24, 25–34, 35–44,
…, > 75. As the probability of death following an SSI is
dependent on age (and thus on strata), the BHAI R package was modified to be compatible with these strata (Personal communication, B. Zacher). The disease outcome
trees, transition probabilities and disability weights were
otherwise the same as though used by Cassini et al. [4].
For full details of the outcome trees, see the supplement
of Cassini et al. or the ECDC BCoDE toolkit [10].
The process of estimation can be summarised into
three steps. The first step is to use the PPS data to estimate the hospital prevalence, which is estimated as
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P =Beta(nobs , N − nobs + 1)
+ (1 − r)Beta(nobs + 1, N − nobs )

(1)

nobs is the number of patients observed with a HAI and N
is the total number of patients in the PPS. This formula
extrapolates from a zero-inflated binomial sample (which
is seen here due to the relatively low prevalence of HAIs)
to a population level estimate using a mixture of two Beta
distributions. Next, this estimate is converted to hospital
incidence,
I =P

LA
LOI

where P is the hospital prevalence from Eq. (1), LA is
the mean length of stay and LOI is the mean length of
infection. For this study, the mean length of stay, LA, was
set to 5.3 days, from the AIHW 2018 statistics on all public hospitals (excluding same-day separations). Following the methodology of Zacher et. al, the mean length
of infection was estimated using the censored length of
infection from the survey and the Grenander estimator.
The final step in the estimation is the population incidence, which is calculated as

Ipop = I × Ndischarges
The survey used in this study was in acute public hospitals for patients over 18 years of age, which
accounts for approximately 60% of separations in public hospitals for patients over 18 years of age, giving
Ndischarges = 3, 713, 513.
To enable comparison between the European and German burden estimates, both datasets were re-aggregated
to match the wider stratification used for estimation in
the Australian setting. It is noted that the data for these
surveys is aggregated into five-year age bands, and so
the lowest age category for these studies is 15–24 (as
opposed to 18–24). However, the burden in those aged
between 15 and 18 is relatively low, so is expected to have
little impact on the results.
As the Australian PPS used the ‘light’ survey design as
specified by the ECDC, McCabe scores are not recorded.
We applied the McCabe score distribution of the ECDC
PPS to Australia, assuming that the McCabe score distribution in Australia would be similar to that observed in
the EU. It is noted that there is little evidence of the applicability or lack thereof of these estimates to the Australian population.

Results
Burden of healthcare‑associated infections in Australia

The estimates for the total number of cases of HAIs
is contained in Table 1. It is estimated that there are
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Table 1 Annual burden of five healthcare associated infections (HAIs), estimated from Australian point prevalence survey data from
2018
Number of HAIs (95% UI)

Deaths
(95% UI)

DALYs
(95% UI)

YLL
(95% UI)

YLD
(95% UI)

SSI

44,238
(31,176–63,797)

876
(617–1263)

13,197
(9298–19,001)

12,982
(9149–18,722)

214
(145–317)

UTI

42,408
(25,200–68,735)

729
(259–1772)

16,087
(5939–37,218)

10,983
(3899–26,704)

4879
(1745–11,659)

CDI

5125
(2360–10,740)

262
(13–836)

2757
(241–8655)

2,635
(128–8403)

127
(21–384)

HAP

51,499
(31,343–82,877)

1904
(462–4430)

39,276
(17,608–77,915)

23,245
(5644–54,078)

15,684
(8038–28,817)

BSI

23,979
(15,658–36,245)

3512
(1874–6075)

46,773
(26,205–79,104)

39,665
(21,159–68,610)

6,964
(3660–12,446)

All

170,574
(135,779–213,898)

7583
(4941–11,135)

122,376
(85,136–172,784)

93,322
(61,443–135,722)

28,669
(18,571–43,924)

Numbers inside brackets indicate 95% uncertainty intervals (UI). SSI surgical site infections, UTI urinary tract infections, CDI Clostridioides difficile infection, HAP
healthcare acquired pneumonia, BSI bloodstream infection, DALYs disability adjusted life years, YLL years of life lost, YLD years lived with disability

Fig. 1 Number of cases of healthcare associated infections per
100,000 population in Australia, presented with previously published
data from the EU and Germany

approximately 7500 deaths each year from HAIs in Australia, with the majority being caused by blood stream
infections (BSI). More than 122,000 DALYs are contributed by HAIs, with the two largest contributors being BSI
and healthcare-acquired pneumonia (HAP).
As is expected, the incidence of HAIs appears inherently age-based (Fig. 1), with those aged greater than 75
having 21 times more cases than those aged 18 to 24. This
is consistent across incidence, DALYs (Fig. 2) and attributable deaths (Fig. 3).

Fig. 2 Number of DALYs from healthcare associated infections,
stratified by age, in Australia, presented with previously published
data from the EU and Germany, normalised by population

Comparison to other conditions

At a rate of 498 DALYs per 100,000 population, HAIs
contribute substantially to the overall burden of disease
in Australia. For comparison, it is estimated that motor
vehicle injuries contribute 180 DALYs, infectious diseases
370 DALYs and respiratory diseases 1380 DALYs per year
in 2015 [15]. While substantially less in magnitude than
cancer and other neoplasms—which contribute 2400
DALYs annually—the health savings on these largely preventable conditions are substantial in Australia (Fig. 4).
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Fig. 3 Number of attributable deaths from healthcare associated
infections, stratified by age, in Australia, presented with previously

Discussion
We have estimated the burden of five HAIs in Australian public hospitals based on point prevalence data from
2018. By computing the number of DALYs, we have provided a comparison point for other health conditions in
Australia. We have also compared these estimates to similar studies in Germany and the EU.
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Previous estimates of the burden of HAIs in Australia
were based on combinations of studies with highly varied collection protocols [9] or based on a study in a single hospital [16]. A previous review of these literature
reported that the burden of HAIs was approximately
83,000 per year, almost half of that estimated here [9].
However, the study noted incomplete data on pneumonia
and bloodstream infections, and if that data were complete, the incidence may be closer to 165,000 per year,
similar to our estimate.
In comparison to the EU and Germany, the incidence
of HAIs in Australia is significantly larger per 100,000
population, particularly in females aged between 55
and 64 (Table 2). Similar to international observations,
the rate of UTIs is higher in females, although a similar
trend is observed in Australian HAP and BSI numbers
compared to international estimates. In both the ECDC
and German settings, the largest contributors to the HAI
burden are UTIs, HAP and SSIs, similar to Australia.
Interestingly, HAP contributes the most DALYs in the
EU estimates, compared with BSI in both Germany and
Australia (Fig. 4).
The uncertainty on our estimates is comparatively high,
likely due to the relatively small number of patients in
this PPS (2767) as opposed to the 273,753 patients in the
ECDC survey and 41,539 in the Germany convenience
sample.
There are potential methodological explanations for
the higher incidence estimate in Australia compared to
German and ECDC estimates. First, the Australian point

Table 2 Annual burden per 100,000 population of five types of healthcare-associated infections from the Australian PPS, and the
ECDC PPS Sample

HAIs

Deaths

DALYs

Sample

SSI

UTI

CDI

HAP

BSI

All

Australia

179.8
(126.7–259.3)

172.4
(102.4–279.4)

20.8
(9.6–43.7)

209.3
(127.4–336.9)

97.5
(63.7–147.3)

693.4
(551.9–869.5)

ECDC

19.9
(17.7–22.2)

128.7
(122.4–135.1)

155.9
(148.6–163.5)

99.4
(94.3–104.6)

14.4
(12.7–16.4)

418.4
(407.3–430)

German

162.8
(137.6–191)

146
(127.1–167.8)

52.6
(41.9–65.8)

228.8
(199.7–262.6)

44.6 (35.6–55.3)

636.3
(589–686.7)

Australia

3.6
(2.5–5.1)

3
(1.1–7.2)

1.1
(0.1–3.4)

7.7
(1.9–18)

14.3
(7.6–24.7)

30.8
(20.1–45.3)

ECDC

3
(1.9–4.1)

4.8
(1.2–9.2)

2.7
(1.1–5.4)

2.3
(2.2–2.4)

0.8
(0–1.6)

13.8
(9.3–19.1)

German

6.1
(1.6–12)

3.7
(3.2–4.2)

7.8
(4.8–11.6)

4
(1.6–8)

2.4
(0.1–5.1)

24.5
(16.9–32.7)

Australia

53.6
(37.8–77.2)

65.4
(24.1–151.3)

11.2
(1–35.2)

159.7
(71.6–316.7)

190.1
(106.5–321.6)

497.5
(346.1–702.4)

ECDC

43.1
(29.1–58.1)

84.4
(43.7–131.1)

48.4
(20.6–88.2)

30.3
(28.8–31.9)

8.3
(0.7–16.2)

216.5
(158.8–280.9)

German

98.6
(51–159.3)

44.6
(38.8–51.3)

102.2
(66.2–148.2)

70.3
(30.1–130.8)

23.8
(2.1–49)

344.7
(256–442.2)

SSI surgical site infections, UTI urinary tract infections, CDI Clostridioides difficile infection, HAP healthcare acquired pneumonia, BSI bloodstream infection, DALYs
disability adjusted life years, YLL years of life lost, YLD years lived with disability
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Fig. 4 Estimated rate of five healthcare associated infections, normalised by population, in Australia, presented with previously published data from
Europe and Germany

prevalence survey was performed in large acute public
hospitals, whereas the European surveys were performed
in a wider range of facilities. Second, the number of
separations used for the EU estimates is an approximation derived from the number of patient-days, whereas
we have the actual total number of separations, but have
assumed the percentage of these that were in adults and
in public, acute hospitals.
The findings in this study are subject to the same
limitations of the source PPS study, including selection bias, restriction to public hospitals and the lack
of patient-level factors present in the data. That study,
while unique in being the first Australian PPS since
1984, included only larger hospitals (nine ‘Principal’
and 10 ‘Group A’ hospitals), which may have a higher
prevalence of HAIs than smaller hospitals. These larger
hospital categories, however, do represent 60% of public hospital separations among adults. We deliberately
focussed our estimate on public hospitals rather than
including the private health system given the casemix
is likely to differ substantially and we have no PPS
data from this sector. Although we have used a very

similar methodology to other studies overseas, these
limitations mean that direct comparison between studies is challenging. Further work is needed to estimate
the burden of HAIs in the private sector and among
children.
We are also limited by the number of sample patients.
Although 2767 patients is substantially more than a
number of single site studies in the same setting, it is
orders of magnitude less than the German and EU point
prevalence surveys. The impact of this limitation is that
the uncertainty in our estimates is relatively high, particularly when stratified by even broad age bands.
We utilised the McCabe score distribution from the
European point prevalence survey, as the Australian
PPS used the “light” definition and so did not collect
its own scores. There is a large number of “avoidable”
hospital stays in Australia, even in the acute hospitals
that were the focus of the PPS. Therefore, the use of
the European McCabe scores would overestimate the
severity of underlying disease, and thus underestimate
the DALYs, as assumed remaining life expectancies
would be lower.
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Conclusions
HAIs are a significant public health issue in Australia
when compared with other health conditions. Our findings are consistent with HAI estimates in European settings. Of note, is the large contributions that pneumonia
and BSI have on overall burden and in particular deaths
and DALYs. This study shows the need for continued
investment in the prevention of HAIs in Australia, and
importantly for robust, national coordinated surveillance
of these conditions.
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